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Goals
1. Perform a chemical screen to find 
drugs that reduce the volume/growth 
of tumors
2. Safer and more effective way to 
combat cancer 
3. Understand the biological pathways 
and their effect on Drosophila models
Agenda
• Background Information
• Drug Screen Process
• Results 
• Conclusion
• Glioblastoma multiforme
– Most malignant form of the highest-grade glioma
– Poor prognosis
Background Information
Tyrosine Kinase Inhibitors
• Tyrosine kinase inhibitors
– Blocks function of epidermal growth factor receptor (EGFR)
• EGFR
– Serves as an “antenna,” receiving signals from other cells 
and the environment that tell the cell to grow and divide 
– Larger amount on surface of cancer cells
Cancer Cell
Tyrosine kinase 
inhibitor
EGFR
• Drosophila melanogaster model
– Has been shown to accurately demonstrate 
human glioma growth
– Shares 70 percent of disease genes with humans; 
including 2 most frequent oncogenic pathways
• Ras/MAPK: Oncogenic mutation
• Pi3K: Growth regulatory 
Experimental Model
Experimental Model
• Drosophila melanogaster model
– Two types of flies:
• 𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖, 𝑟𝑎𝑠𝑣12
– 𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖 works to shut off a tumor-suppressor                        
gene (Pten)
– 𝑟𝑎𝑠𝑣12 works to promote tumor growth
• Repo GFP
– Repo works to drive the tumor progression,                             
cancer growth cannot progress without it
– GFP allows the glia cells in the brain to fluoresce under                
UV light
What are Pathways?
• Definition:
– A series of actions 
among molecules 
within a cell that 
causes a certain 
change within that cell
– Gene-regulation 
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Drug Screen Process
Reestablishing fly 
colonies.
1.
Crossing 𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖 , 
𝑟𝑎𝑠𝑣12 virgins with 
Repo GFP males.
3.
Day 3: 
Collecting larvae 
from cross and 
placing into vials 
containing drug 
laced food.
4.
Day 5 and 6: 
Recollecting, 
dissecting, 
mounting, and 
imaging the larvae. 
5.
Collecting female 
virgins from 
𝑃𝑡𝑒𝑛𝑅𝑁𝐴𝑖 , 𝑟𝑎𝑠𝑣12
stock.
2.
Results
• P1G8
Repo control brain Glioma brain Our screen: 300 µM
Results (cont.)
• P1G10 
Previous: (10µM) Our screen: 300 µMGlioma 
Future Directions
• EC50 Curve 
– Determines at what point the drug kills 
50% of the population
– Why is this important?
• Perform western blots
– Determine proteins effected by the drugs, 
how pathways are affected
• Mammalian cell trials with                      
Dr. Pitychoutis
Future Directions (cont.)
• Additional preliminary screenings
• AZD 3759 (ongoing)
Glioma brain + Lapatinib (GW-
572016) Ditosylate
Repo control brain Glioma brain
• Gefitinib 
– In clinical phase 4, showing promise
Glioma Glioma + Gefitinib (10uM)
Future Directions (cont.)
Roadblocks
• Reestablishing fly 
colonies
– Male : Female 
Ratios 
– Live organisms 
• Virgin collection
Conclusion
• PIG8 & P1G10 at 300 µM
– May be too toxic for larvae
– Next step will be EC50 curve 
• Utilize data to better understand how 
these tyrosine kinase inhibitors affect 
tumor growth/volume 
– Will help improve therapies and thereby 
prognosis of glioma patients
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